First-line Immunotherapy in Metastatic Urothelial Carcinoma

被引：3
|
作者：
Ghatalia, Pooja [1 ]
Zibelman, Matthew [1 ]
Geynisman, Daniel M. [1 ]
Plimack, Elizabeth R. [1 ]
机构：
[1] Fox Chase Canc Ctr, Dept Hematol Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA
来源：
EUROPEAN UROLOGY FOCUS | 2020年 / 6卷 / 01期
关键词：
CISPLATIN; CHEMOTHERAPY; ATEZOLIZUMAB; METHOTREXATE; VINBLASTINE; MULTICENTER; DOXORUBICIN; TRIAL;
D O I：
10.1016/j.euf.2019.04.015
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：45 / 47
页数：3
相关论文
共 50 条
  • [1] Reevaluating immunotherapy's potential in first-line metastatic urothelial carcinoma
    Castano-Amores, Celia
    Nieto-Gomez, Pelayo
    JOURNAL OF CHEMOTHERAPY, 2024,
  • [2] First-line treatment of metastatic urothelial carcinoma: an update
    von Amsberg, Gunhild
    Retz, Margitta
    De Santis, Maria
    Niegisch, Gunter
    ONKOLOGIE, 2022, 28 (09): : 792 - 798
  • [3] Comparative effectiveness analysis of first-line immunotherapy versus chemotherapy in metastatic urothelial carcinoma of the bladder
    Chakiryan, Nicholas H.
    Jiang, Da David
    Gillis, Kyle A.
    Green, Elizabeth
    Hajiran, Ali
    Hugar, Lee
    Zemp, Logan
    Zhang, Jingsong
    Jain, Rohit
    Chahoud, Jad
    Li, Roger
    Sexton, Wade
    Manley, Brandon J.
    Gilbert, Scott M.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2022, 40 (03) : 107.e11 - 107.e17
  • [4] Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy
    Tassinari, Elisa
    Mollica, Veronica
    Nuvola, Giacomo
    Marchetti, Andrea
    Rosellini, Matteo
    Massari, Francesco
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 1945 - 1960
  • [5] Medical oncologists' first-line treatment preferences in metastatic urothelial carcinoma
    Apolo, Andrea B.
    Cambron-Mellott, M. Janelle
    Beusterien, Kathleen
    Seal, Brian S.
    Maculaitis, Martine C.
    Bernstein, Andrew
    Epperson, Megan
    Jeffress, Mara Lisa
    Doleh, Yunes
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [6] Beyond first-line systemic treatment for metastatic urothelial carcinoma of the bladder
    E. El Rassy
    T. Assi
    Z. Bakouny
    N. Pavlidis
    J. Kattan
    Clinical and Translational Oncology, 2019, 21 : 280 - 288
  • [7] Bempegaldesleukin/Nivolumab and Challenges in First-line Treatment of Metastatic Urothelial Carcinoma
    Miron, Benjamin
    Geynisman, Daniel M.
    EUROPEAN UROLOGY, 2022, 82 (04) : 374 - 376
  • [8] Beyond first-line systemic treatment for metastatic urothelial carcinoma of the bladder
    El Rassy, E.
    Assi, T.
    Bakouny, Z.
    Pavlidis, N.
    Kattan, J.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (03): : 280 - 288
  • [9] CROSS-REACTIVITY BETWEEN THE FIRST-LINE CHEMOTHERAPY AND SUBSEQUENT IMMUNOTHERAPY IN PATIENTS WITH UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA
    Hamaya, Tomoko
    Hatakeyama, Shingo
    Ozaki, Kai
    Okita, Kazutaka
    Hashimoto, Yasuhiro
    Ohyama, Chikara
    JOURNAL OF UROLOGY, 2022, 207 (05): : E1017 - E1017
  • [10] First-line treatment of metastatic urothelial carcinoma Update immuno-oncology
    Zacharis, A.
    Gruellich, C.
    UROLOGE, 2020, 59 (07): : 797 - 803
12345